Bench‐to‐bedside translation of dendrimers: Reality or utopia? A concise analysis

[1]  P. Gennes,et al.  Statistics of « starburst » polymers , 1983 .

[2]  G. Springer.  T and Tn, general carcinoma autoantigens. , 1984, Science.

[3]  C. Hawker,et al.  Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules , 1990 .

[4]  J. C. Roberts,et al.  Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. , 1996, Journal of biomedical materials research.

[5]  Covering the spread , 1997, Science.

[6]  J. Fréchet,et al.  Convergent dendrons and dendrimers: from synthesis to applications. , 2001, Chemical reviews.

[7]  Xiaojun Cao,et al.  A NEW CONVERGENT APPROACH TO DENDRITIC MACROMOLECULES , 2002 .

[8]  J. Fréchet,et al.  Discovery of dendrimers and dendritic polymers: A brief historical perspective* , 2002 .

[9]  F. Szoka,et al.  Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. , 2002, Bioconjugate chemistry.

[10]  A. Caminade,et al.  Dendrislides, dendrichips: a simple chemical functionalization of glass slides with phosphorus dendrimers as an effective means for the preparation of biochips , 2003 .

[11]  A. Caminade,et al.  Dendrimeric coating of glass slides for sensitive DNA microarrays analysis. , 2003, Nucleic acids research.

[12]  M. Wadman.  Early success claimed for Zerhouni's NIH roadmap , 2004, Nature.

[13]  R. Roy.  New trends in carbohydrate-based vaccines. , 2004, Drug discovery today. Technologies.

[14]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[15]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[16]  D. Tomalia.  Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .

[17]  F. Szoka,et al.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.

[18]  X P Chen,et al.  Target validation: A door to drug discovery. , 2007, Drug discoveries & therapeutics.

[19]  W. Heideman,et al.  Developmental toxicity of low generation PAMAM dendrimers in zebrafish. , 2007, Toxicology and applied pharmacology.

[20]  L. Stanberry,et al.  VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection , 2007, International journal of nanomedicine.

[21]  P. Jain,et al.  Au nanoparticles target cancer , 2007 .

[22]  A. Ghaly,et al.  Effect of Flow Characteristics on Online Sterilization of Cheese Whey in UV Reactors , 2007, Applied biochemistry and biotechnology.

[23]  W. Chan,et al.  Nanotoxicity: the growing need for in vivo study. , 2007, Current opinion in biotechnology.

[24]  F. Hefti.  Requirements for a lead compound to become a clinical candidate , 2008, BMC Neuroscience.

[25]  M. Grinstaff,et al.  Therapeutic and diagnostic applications of dendrimers for cancer treatment. , 2008, Advanced drug delivery reviews.

[26]  S. Ganta,et al.  A review of stimuli-responsive nanocarriers for drug and gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[27]  N. K. Jain,et al.  Application of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability , 2008, Expert opinion on drug metabolism & toxicology.

[28]  A. Gabizon,et al.  Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. , 2008, Clinical lymphoma & myeloma.

[29]  D. Butler.  Translational research: Crossing the valley of death , 2008, Nature.

[30]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[31]  V. Venditto,et al.  The 8 year thicket of triazine dendrimers: strategies, targets and applications , 2010, Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[32]  N. K. Jain,et al.  Surface-Engineered Dendrimers: a Solution for Toxicity Issues , 2009, Journal of biomaterials science. Polymer edition.

[33]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[34]  R. Kannan,et al.  Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.

[35]  Z. Gu,et al.  New-generation biomedical materials: Peptide dendrimers and their application in biomedicine , 2010 .

[36]  G. Kaushik,et al.  Poly propyl ether imine (PETIM) dendrimer: a novel non-toxic dendrimer for sustained drug delivery. , 2010, European journal of medicinal chemistry.

[37]  Biological properties of phosphorus dendrimers , 2010 .

[38]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[39]  V. S. Saji,et al.  Nanotechnology in biomedical applications: a review , 2010 .

[40]  Michael A W Eaton,et al.  How do we develop nanopharmaceuticals under open innovation? , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[41]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[42]  Meifang Zhu,et al.  Targeted delivery of doxorubicin into cancer cells using a folic acid–dendrimer conjugate , 2011 .

[43]  Mingwu Shen,et al.  Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy , 2011, International journal of nanomedicine.

[44]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[45]  Mark W Grinstaff,et al.  Biomedical applications of dendrimers: a tutorial. , 2011, Chemical Society reviews.

[46]  R. Roy,et al.  Organic chemistry and immunochemical strategies in the design of potent carbohydrate-based vaccines. , 2011, Chimia.

[47]  R. Haag,et al.  Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. , 2012, Chemical Society reviews.

[48]  J. Majoral,et al.  Dendrimer therapeutics: covalent and ionic attachments , 2012 .

[49]  A. Tocchio,et al.  Nanotechnology in Medicine: From Inception to Market Domination , 2012, Journal of drug delivery.

[50]  S. Rayala,et al.  Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications , 2012, International journal of nanomedicine.

[51]  Jayant Khandare,et al.  Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. , 2012, Chemical Society reviews.

[52]  G. Daston,et al.  Toxicology of nanoparticles. , 2012, Advanced drug delivery reviews.

[53]  Yiyun Cheng,et al.  Dendrimer-based drug delivery systems : from theory to practice , 2012 .

[54]  R. Roy,et al.  Glycodendrimers as functional antigens and antitumor vaccines , 2012 .

[55]  J. Majoral,et al.  Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. , 2013, Advanced drug delivery reviews.

[56]  J. Majoral,et al.  Copper in dendrimer synthesis and applications of copper–dendrimer systems in catalysis: a concise overview , 2013 .

[57]  Pallavi Sethi,et al.  Tumor microenvironment and nanotherapeutics. , 2013, Translational cancer research.

[58]  Xiangyang Shi,et al.  Dendrimer-based nanodevices for targeted drug delivery applications. , 2013, Journal of materials chemistry. B.

[59]  J. Majoral,et al.  Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry , 2013 .

[60]  René Roy,et al.  Glycodendrimers: versatile tools for nanotechnology , 2013 .

[61]  P. Choyke,et al.  Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.

[62]  Youngmi Kim,et al.  ROS-Responsive Activatable Photosensitizing Agent for Imaging and Photodynamic Therapy of Activated Macrophages , 2013, Theranostics.

[63]  Jeanine Giarolla Vargas.  Dendrimers: from the art of building precise molecules to the dissemination through the world , 2013 .

[64]  V. Venditto,et al.  Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.

[65]  R. Duncan,et al.  Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. , 2013, Nanomedicine.

[66]  Dong Choon Hyun,et al.  Engineered nanoparticles for drug delivery in cancer therapy. , 2014, Angewandte Chemie.

[67]  Xiangyang Shi,et al.  Impact of dendrimer surface functional groups on the release of doxorubicin from dendrimer carriers. , 2014, The journal of physical chemistry. B.

[68]  Y. Barenholz,et al.  Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap , 2022 .

[69]  S. Kannan,et al.  Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications , 2014, Journal of internal medicine.

[70]  J. Lovrić,et al.  Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.

[71]  Dzmitry G. Shcharbin,et al.  Recent Patents in Dendrimers for Nanomedicine: Evolution 2014 , 2014 .

[72]  Mingwu Shen,et al.  Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. , 2014, ACS applied materials & interfaces.

[73]  V. Torchilin.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[74]  S. Svenson,et al.  What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[75]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[76]  Lin-Ping Wu,et al.  Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. , 2015, Bioconjugate chemistry.

[77]  Jean‐François Morin,et al.  Recent Advances in Click Chemistry Applied to Dendrimer Synthesis , 2015, Molecules.

[78]  Rahul S. Kalhapure,et al.  Dendrimers – from organic synthesis to pharmaceutical applications: an update , 2015, Pharmaceutical development and technology.

[79]  O. Wolfbeis.  An overview of nanoparticles commonly used in fluorescent bioimaging. , 2015, Chemical Society reviews.

[80]  A. Fernández-Medarde,et al.  Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[81]  Mattie R. Davenport.  Covering The Spread , 2015 .

[82]  J. Tsai,et al.  There is no better time than the present: nanotechnology as a disruptive innovation for drug development. , 2015, Drug discovery today.

[83]  L. Lévy,et al.  Delivering nanomedicines to patients: a practical guide. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[84]  Ali Khademhosseini,et al.  Patient-Inspired Engineering and Nanotechnology. , 2015, ACS nano.

[85]  Xiangyang Shi,et al.  RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells. , 2015, Colloids and surfaces. B, Biointerfaces.

[86]  Mingwu Shen,et al.  Encapsulation of doxorubicin within multifunctional gadolinium-loaded dendrimer nanocomplexes for targeted theranostics of cancer cells , 2015 .

[87]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[88]  F. Bonhomme,et al.  Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate. , 2016, Organic & biomolecular chemistry.

[89]  J. Calixto,et al.  Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies , 2016, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[90]  A. Caminade,et al.  The specific functionalization of cyclotriphosphazene for the synthesis of smart dendrimers. , 2016, Dalton transactions.

[91]  J. Majoral,et al.  Compound high-quality criteria: a new vision to guide the development of drugs, current situation. , 2016, Drug discovery today.

[92]  P. Prasad,et al.  Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy. , 2016, Chemical reviews.

[93]  K. Ranjit,et al.  NANOPARTICLE: AN OVERVIEW OF PREPARATION, CHARACTERIZATION AND APPLICATION , 2016 .

[94]  Robert Langer,et al.  Evolution of macromolecular complexity in drug delivery systems. , 2017, Nature reviews. Chemistry.

[95]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[96]  H. Yabu,et al.  Virus-like particles composed of sphere-forming polystyrene-block-poly(t-butyl acrylate) (PS-b-PtBA) and control of surface morphology by homopolymer blending , 2017 .

[97]  Celia N. Cruz,et al.  The evolving landscape of drug products containing nanomaterials in the United States. , 2017, Nature nanotechnology.

[98]  J. Majoral,et al.  Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches , 2017 .